全球磺达肝癸钠市场 – 行业趋势及 2030 年预测

磺达肝癸钠市场分析及规模

根据美国心脏协会的数据，2019 年，60 至 79 岁男性心血管疾病的发病率约为 77.2%，女性约为 78.2%。大多数疾病（如心脏感染和骨科疾病）预计在未来几年将推动市场发展。据观察，由于仿制药价格较低且疗效显著，预计磺达肝癸钠市场的仿制药部分将占据主导地位。

Data Bridge Market Research 分析了 2023-2030 年预测期内磺达肝癸钠市场的增长率。在上述预测期内，磺达肝癸钠市场的预期复合年增长率约为 6.7%。2022 年市场价值为 5.7494 亿美元，到 2030 年将增长至 9.6591 亿美元。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外，Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、渠道分析、定价分析和监管框架。

磺达肝癸钠市场范围和细分

Market Definition

Fondaparinux is a synthetic anticoagulant used to prevent the formation of blood clots based on the pentasaccharide sequence, which makes up the minimal antithrombin binding region of heparin. It is an indirect inhibitor of factor Xa having the molecular weight same like heparins. Fondaparinux has a longer half-life than heparin and does not interact with platelets.  

Global Fondaparinux Market Dynamics

Drivers

• Growing Risk of Elderly Population Having CVD Risk

As per the records of the United Nations, World Population Prospects: The 2019 Revision, by 2050, one in six people in the world is aged above 65 years, up from one in 11 in 2019. Elderly population is more susceptible to chronic illnesses and it requires immediate and effective treatment for better clinical outcomes, the market is projected to be impacted considerably. In 2019, according to the American Heart Association, the occurrence rate of cardiovascular disease between age 60 and 79 years was 77.2% for men and 78.2% for women.

• Growing Healthcare Expenditure

The rising net profit of several key market players and its associated funds and expenditure from various organizations leads to the growth of the market. For instance, in May 2020, Dr. Reddy's Laboratories announced a 4% growth in its consolidated net profit at Rs 1,949.8 crore for the financial year ended March 31, 2020, wherein the global generics accounted to INR 3,640 crore, with an increase by 20% from F.Y. 2019.

Opportunities

• Increasing Demand of Generics  Drug Type

As per the study published in the Journal of American Heart Association, 2020, fondaparinux was found to exhibit an augmented efficiency in the reduction of venous thromboembolism, than low molecular weight heparin, during the treatment for perioperative surgical thromboprophylaxis. Furthermore, as per the research study that is published in the American Heart Association Journal, 2018, compared to enoxaparin for the treatment of non-ST-elevation acute coronary syndrome (NSTE-ACS) patients, fondaparinux was found to be comparatively cost-effective in a Canadian hospital setting.

• Increased Condition of Deep Vein Thrombosis (DVT)

Deep Vein Thrombosis (DVT) is the type of condition in which clot formation takes place in deep veins, and its associated severity may lead to pulmonary embolism. As per the research article published in Medscape, 2019, death from DVT-associated massive pulmonary embolism causes as many as 300,000 deaths annually in the U.S. This boosts the market growth.

Restraints/Challenges

• High Cost of Treatment

The increased expenditure that is required for the diverse treatment processes hamper the market growth. Frequent market players make huge investments in manufacturing new and advanced treatment procedures to increase the recovery process, and in return, the cost is increased.

This fondaparinux market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the fondaparinux market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Fondaparinux Market

COVID-19 has dramatically impacted the fondaparinux market is not exception. Though, the use of heparin is witnessed to show a decreased mortality rate in COVID-19 patients. As per the Journal of Cardiovascular Pharmacology, 2020, the initial results from the study focused the safe and effective use of fondaparinux to decrease the rate of mortality among COVID-19 patients. It is also recommended that fondaparinux be used to some extent because of its long half-life and lack of an antidote. Therefore, different opinions given regarding the usage of fondaparinux in COVID-19 patients, the studied market is projected to be impacted during the COVID-19 pandemic.

Recent Development:

• In 2021, Bayer introduced Vynyty Citrus during the International Symposium on Horticulture in Europe named SHE2021. It is its latest biological and pheromone-based crop protection product for controlling citrus farm pests.

Global Fondaparinux Market Scope

The fondaparinux market is segmented on the basis of types, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Types

• Deep Vein Thrombosis
• Pulmonary Embolism

Treatment

• Medication
• Others

Route of Administration

• Parenteral
• Others

Product type

• Branded
• Generics

End-Users

• Hospitals
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacies
• Others

Fondaparinux Market Regional Analysis/Insights

The fondaparinux market is analyzed and market size insights and trends are provided by types, treatment, route of administration, distribution channel and end-user as referenced above.

磺达肝癸钠市场报告涉及的主要国家 包括北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区的亚太地区其他地区、沙特阿拉伯、阿联酋、南非、埃及、以色列、中东和非洲其他地区、巴西、阿根廷以及南美洲的其他地区。

由于全球参与者专注于新技术或现有药物的配方，北美在市场上占据主导地位。

由于药物成瘾现象猖獗以及仿制药数量众多，亚太地区未来几年预计将实现增长。

报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和国内市场监管变化。此外，在提供国家数据预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈竞争或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。 

竞争格局和全球磺达肝癸钠市场份额分析

磺达肝癸钠市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对磺达肝癸钠市场的关注有关

磺达肝癸钠市场的主要参与者包括：

• 辉瑞公司（美国）
• 拜耳公司（德国）
• 葛兰素史克公司（英国）
• 勃林格殷格翰国际有限公司 (德国)
• 赛诺菲（法国）
• Apotex（加拿大）
• 雅培（美国）
• 阿斯彭控股 (南非)
• 百时美施贵宝公司 (美国)
• 卫材株式会社（日本）
• Aurobindo Pharma（印度）
• Mylan NV（美国）

SKU-56820